

**Minutes of the September 2, 2016
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical
Services**

Members present

Bill Ladwig; Richard Holm; Dana Darger; Lenny Petrik; Kelley Oehlke; James Engelbrecht; Mikel Holland; Timothy Soundy

DSS staff present

Mike Jockheck, RPh

Administrative business

The P&T meeting was called to order by D. Darger at 1:00 p.m. The minutes of the June meeting were presented. R. Holm made a motion to approve. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior authorization update and statistics

The committee reviewed the prior authorization (PA) activity for July 2016. There were a total of 3,200 PAs processed in the month of July, with 99.94% of those requests responded to in less than eight hours. There were 2,599 requests (81%) received electronically and 601 requests (19%) received by fax.

Analysis of the top 15 therapeutic classes and drug spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 04/01/2016 – 06/30/2016. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, insulins, and anticonvulsants, misc. The top 15 therapeutic classes make up 38.10% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 14.56% of total claims. The committee also reviewed SD Medicaid drug spend for 2013 – 2016.

Evzio/Narcan second review

Narcan nasal spray was reviewed at the June meeting. At that time, the committee asked that the Evzio PA form be brought back to the September meeting for review. Tommy Begres, representing Adapt Pharmaceuticals, spoke regarding Narcan nasal spray. A motion was made by T. Soundy to monitor utilization and to leave Evzio on prior authorization. R. Holm seconded the motion. The motion was approved unanimously.

Opioid utilization and strategies for management

The state has asked the committee to provide insight on ways to manage opioid utilization. Best practices guidelines, developed by CMS, were provided to committee members for review. Opioid utilization data showing overall utilization,

top recipients by script count, top prescribers, and top counties were provided to the committee for review. Options discussed by the committee included: physician lettering, methadone PA, early refill edits, PDMP, proDUR edits, and lock-in.

Gabapentin and pregabalin second review

The committee reviewed utilization information for gabapentin and pregabalin. There was no public comment. J. Engelbrecht made a motion to place pregabalin on prior authorization. R. Holm seconded the motion. The motion was approved unanimously.

Xenazine second review

A prior authorization was placed on Xenazine at the June meeting and the PA form was developed and brought to the committee for review. There was no public comment. J. Englebrecht made a motion to approve the PA form. T. Soundy seconded the motion. The motion was approved unanimously.

Onfi review

The committee reviewed Onfi clinical information. There was no public comment. The topic was tabled until the December meeting.

Benzodiazepine review

The committee reviewed benzodiazepine utilization. There was no public comment. The topic was tabled.

Zinbryta review

The committee reviewed Zinbryta clinical information. M. Olmon, representing Abbvie spoke. J. Englebrecht made a motion to place Zinbryta on prior authorization. L. Petrik seconded the motion. The motion was approved unanimously. A form will be developed and brought to the December meeting.

Byvalson review

The committee reviewed Byvalson clinical information. There was no public comment. R. Holm made a motion to place Byvalson on prior authorization. T. Soundy seconded the motion. The motion was approved unanimously. A form will be developed and brought to the December meeting.

The next meeting is scheduled for December 9, 2016. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.